Nicolas Barthelemy has served as a member of our board of directors since March 2017. Mr. Barthelemy brings over 29 years of health care industry experience to the Fluidigm Board, having served in multiple senior executive roles in the biopharmaceutical, life science tools, and molecular diagnostics sectors. He previously served as President and CEO of Biotheranostics, a privately held molecular diagnostics company, from 2014 until February 2017. Just prior to that, he served as President of Global Commercial Operations at Life Technologies, a $4 billion life science industry leader that was acquired by Thermo Fisher Scientific in 2014. Prior to that position, he led the $850 million Cell Systems Division for five years at Life Technologies. Before Life Technologies, Mr. Barthelemy was with Biogen for eight years in operational and commercial roles of increasing responsibility, including Vice President of Manufacturing. He began his career with Merck & Co., Inc. as a Project Engineer in the Vaccine Division. Mr. Barthelemy currently also serves on the boards of directors of Repligen Corporation and Twist Bioscience Corporation. He received an M.S. in chemical engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et de Chimie Industrielles in Paris.